Previous 10 | Next 10 |
Nano cap Marinus Pharmaceuticals ( MRNS +32.6% ) is up on triple normal volume on the heels of its public offering of 28M common shares at $1.25, apparently a more bullish price than investors were expecting (possibly aided by the convertible offering below). More news on: Marinus Phar...
RADNOR, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the pricing of an underwritten public offering of 28,000,000 shares of common stock at a public offering price of $1.25 per s...
RADNOR, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in t...
Marinus Pharmaceuticals (NASDAQ: MRNS ) announces clinical and regulatory updates for its orphan seizure programs in tuberous sclerosis complex (TSC), CDKL5 deficiency disorder (CDD) and PCDH19-related epilepsy (PCDH19-RE). More news on: Marinus Pharmaceuticals, Inc., Healthcare sto...
Initiation of Phase 2 trial evaluating ganaxolone in tuberous sclerosis complex planned for 1H 2020 European Medicines Agency Orphan Drug Designation granted for ganaxolone for the treatment of CDKL5 deficiency disorder CDKL5 deficiency disorder pivotal Phase 3 trial on-track for...
100% of evaluable patients in target dose had no relapse during the four-week follow-up period Independent objective EEG seizure analysis confirms target dose Ganaxolone effective regardless of prior AED treatment and across diverse disease etiologies for RSE KOL call and live...
Gainers: Aurinia Pharmaceuticals (NASDAQ: AUPH ) +95% . More news on: Aurinia Pharmaceuticals Inc., Duluth Holdings Inc., Atreca, Inc., Stocks on the move, Read more ...
Marinus Pharmaceuticals (NASDAQ: MRNS ) is up 3% premarket while Axsome Therapeutics (NASDAQ: AXSM ) is down 8% following Sage Therapeutics' failed Phase 3 study of SAGE-217 in major depressive disorder (MDD). More news on: Marinus Pharmaceuticals, Inc., Axsome Th...
RADNOR, Pa., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts highlighting ganaxolone data...
Marinus Pharmaceuticals (NASDAQ: MRNS ): Q3 GAAP EPS of -$0.26 misses by $0.02 . More news on: Marinus Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...